Search Results - "Ghobrial, I. M."

Targeting MYC in multiple myeloma by Jovanović, K. K., Roche-Lestienne, C., Ghobrial, I. M., Facon, T., Quesnel, B., Manier, S.

“…Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway…”
Get full text

Bone Marrow Microenvironment in Multiple Myeloma Progression by Ghobrial, I. M., Sacco, A., Leleu, X., Roccaro, A. M., Manier, S.

“…Substantial advances have been made in understanding the biology of multiple myeloma (MM) through the study of the bone marrow (BM) microenvironment. Indeed,…”
Get full text

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma by Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M

“…The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL)…”
Get full text

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma by Manier, S., Park, J., Capelletti, M., Bustoros, M., Freeman, S. S., Ha, G., Rhoades, J., Liu, C. J., Huynh, D., Reed, S. C., Gydush, G., Salem, K. Z., Rotem, D., Freymond, C., Yosef, A., Perilla-Glen, A., Garderet, L., Van Allen, E. M., Kumar, S., Love, J. C., Getz, G., Adalsteinsson, V. A., Ghobrial, I. M.

“…Liquid biopsies including circulating tumor cells (CTCs) and cell-free DNA (cfDNA) have enabled minimally invasive characterization of many cancers, but are…”
Get full text

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma by Manier, S, Powers, J T, Sacco, A, Glavey, S V, Huynh, D, Reagan, M R, Salem, K Z, Moschetta, M, Shi, J, Mishima, Y, Roche-Lestienne, C, Leleu, X, Roccaro, A M, Daley, G Q, Ghobrial, I M

“…MYC is a major oncogenic driver of multiple myeloma (MM) and yet almost no therapeutic agents exist that target MYC in MM. Here we report that the let-7…”
Get full text

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials by Potts, B C, Albitar, M X, Anderson, K C, Baritaki, S, Berkers, C, Bonavida, B, Chandra, J, Chauhan, D, Cusack, Jr, J C, Fenical, W, Ghobrial, I M, Groll, M, Jensen, P R, Lam, K S, Lloyd, G K, McBride, W, McConkey, D J, Miller, C P, Neuteboom, S T C, Oki, Y, Ovaa, H, Pajonk, F, Richardson, P G, Roccaro, A M, Sloss, C M, Spear, M A, Valashi, E, Younes, A, Palladino, M A

“…The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration…”
Get more information

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib by Weisberg, E, Azab, A K, Manley, P W, Kung, A L, Christie, A L, Bronson, R, Ghobrial, I M, Griffin, J D

“…Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow…”
Get full text

Targeting Apoptosis Pathways in Cancer Therapy by Ghobrial, Irene M, Witzig, Thomas E, Adjei, Alex A

“…Apoptosis, or programmed cell death, is a mechanism by which cells undergo death to control cell proliferation or in response to DNA damage. The understanding…”
Get full text

The use of novel agents in the treatment of relapsed and refractory multiple myeloma by Laubach, J P, Mahindra, A, Mitsiades, C S, Schlossman, R L, Munshi, N C, Ghobrial, I M, Carreau, N, Hideshima, T, Anderson, K C, Richardson, P G

“…Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well…”
Get full text

Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia by Sacco, A, Ghobrial, I M, Roccaro, A M

“…Bone marrow microenvironment has been shown to play a crucial role in supporting the pathogenesis and the progression of several B-cell malignancies, including…”
Get more information

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine by Batth, I.S., Mitra, A., Manier, S., Ghobrial, I.M., Menter, D., Kopetz, S., Li, S.

“…Current trajectory of clinical care is heading in the direction of personalized medicine. In an ideal scenario, clinicians can obtain extensive diagnostic and…”
Get full text

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix by Glavey, S V, Naba, A, Manier, S, Clauser, K, Tahri, S, Park, J, Reagan, M R, Moschetta, M, Mishima, Y, Gambella, M, Rocci, A, Sacco, A, O'Dwyer, M E, Asara, J M, Palumbo, A, Roccaro, A M, Hynes, R O, Ghobrial, I M

“…The extracellular matrix (ECM) is a major component of the tumor microenvironment, contributing to the regulation of cell survival, proliferation,…”
Get full text

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine by Batth, I.S., Mitra, A., Manier, S., Ghobrial, I.M., Menter, D., Kopetz, S., Li, S.

Get full text

Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics by Dimopoulos, M.A., Kastritis, E., Ghobrial, I.M.

“…Waldenström's macroglobulinemia (WM) is a rare, low-grade malignancy with no established standard of care. Rituximab regimens are most commonly used, supported…”
Get full text

Targeting vasculogenesis to prevent progression in multiple myeloma by Moschetta, M, Mishima, Y, Kawano, Y, Manier, S, Paiva, B, Palomera, L, Aljawai, Y, Calcinotto, A, Unitt, C, Sahin, I, Sacco, A, Glavey, S, Shi, J, Reagan, M R, Prosper, F, Bellone, M, Chesi, M, Bergsagel, L P, Vacca, A, Roccaro, A M, Ghobrial, I M

“…The role of endothelial progenitor cell (EPC)-mediated vasculogenesis in hematological malignancies is not well explored. Here, we showed that EPCs are…”
Get full text

Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma by GHOBRIAL, I. M, DISPENZIERI, A, HAYMAN, S, PRIBULA, C. G, GERTZ, M. A, BUNDY, K. L, GASTINEAU, D. A, RAJKUMAR, S. V, THERNEAU, T. M, LACY, M. Q, WITZIG, T. E, LITZOW, M. R, CHRISTENSEN, B. R

“…The purpose of this study was to determine the effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. We performed a…”
Get full text

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia by Ghobrial, I M, Redd, R, Armand, P, Banwait, R, Boswell, E, Chuma, S, Huynh, D, Sacco, A, Roccaro, A M, Perilla-Glen, A, Noonan, K, MacNabb, M, Leblebjian, H, Warren, D, Henrick, P, Castillo, J J, Richardson, P G, Matous, J, Weller, E, Treon, S P

“…We examined the combination of the mammalian target of rapamycin inhibitor everolimus with bortezomib and rituximab in patients with relapsed/refractory…”
Get full text

P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA by Hasan Bou Issa, L., Fléchon, L., Laine, W., Ouelkdite, A., Escure, G., Gaggero, S., Ingegnere, T., Sklavenitis Pistofidis, R., Ghobrial, I. M., Facon, T., Mitra, S., Kluza, J., Quesnel, B., Manier, S.

Get full text

The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression by Azab, A K, Weisberg, E, Sahin, I, Liu, F, Awwad, R, Azab, F, Liu, Q, Griffin, J D, Ghobrial, I M

Get full text

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination by Sahin, I, Moschetta, M, Mishima, Y, Glavey, S V, Tsang, B, Azab, F, Manier, S, Zhang, Y, Maiso, P, Sacco, A, Azab, A K, Roccaro, A M, Ghobrial, I M

Get full text